What is Krka, d. d.'s (KRK.WA) StockRank?

MoatMap's StockRank for Krka, d. d. (KRK.WA) is 98/100, with a Strong Buy signal. This is a composite score combining Quality (85), Value (58), and Momentum (71) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Krka, d. d. have an economic moat?

Krka, d. d. (KRK.WA) has a Quality factor score of 85/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Krka, d. d. a buy, hold, or sell?

MoatMap's current signal for Krka, d. d. (KRK.WA) is Strong Buy, based on a StockRank of 98/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Krka, d. d. in?

Krka, d. d. (KRK.WA) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Slovenia).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

KRK.WA

Strong BuyFull HouseAPPROVE

Krka, d. d. · Healthcare · Slovenia · $9.3B · Avg Vol: $26K/d

StockRank

Get insider-trade alerts

P/E (TTM)

19.1x

ROE

16.2%

D/E

0.0x

Dividend %

3.4%

AI CONVICTION THESIS

Krka is a quintessential high-ROIC quality compounder with deep operational moats in generic pharmaceuticals. Its ability to maintain pricing power while delivering consistent dividends makes it a defensive anchor during geopolitical instability. The company is well-positioned to benefit from the 'Quality Compounder' macro theme as investors rotate away from cyclical volatility toward reliable earnings.

COMPANY DESCRIPTION

Krka, d. d. is a leading generic pharmaceutical company based in Slovenia, specializing in prescription pharmaceuticals, non-prescription products, and animal health products. The company holds a dominant market position in Central, Eastern, and South-Eastern Europe. Its competitive moat is sustained by vertically integrated development and production capabilities, a broad portfolio of high-quality generic drugs, and an extensive marketing-and-sales network.

FINANCIAL SUMMARY (PLN)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	7.5B	7.8B	8.3B	8.9B	5.9%	9.2B	9.4B	10.0B	6.0%
EPS (PLN)	50.73	44.00	50.34	57.32	4.2%	60.42	—	—	—
Shares	32.8M	32.8M	32.8M	32.8M	0.0%	30.3M	—	—	—
Debt	51.4M	52.1M	57.1M	79.7M	15.7%	80.6M	—	—	—
Equity	9.2B	9.4B	9.6B	10.2B	3.6%	—	—	—	—
Op CF	2.0B	986.1M	1.6B	2.3B	4.2%	2.2B	—	—	—
Inv CF	331.6M	-1.5B	325.9M	-830.1M	—	—	—	—	—
Fin CF	-811.6M	-997.3M	-1.1B	-1.4B	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+0.2%

SMA 50SMA 200

$300.99

RSI (14)

50.5

52W High

$316.65

From 52W High

1.0%

SCORE BREAKDOWN

Quality

ROIC

20.6%90.7

ROE

16.2%83.9

GP/Assets

41.2%79.5

Op. Margin

28.5%90.7

FCF/Assets

12.9%91.1

Piotroski

783.9

Int. Cover

50.0x89.3

D/E Ratio

0.01x87.2

Current Ratio

4.21x67.1

Value

P/E (TTM)

19.1x62.2

EV/EBITDA

12.9x56.7

P/FCF

20.3x61.7

P/B

3.1x45.6

P/S

3.8x50.2

Div Yield

3.4%76.3

Momentum

52W High %

95%94.3

RS 6M

-16%44.7

SMA 50/200

1.11x76.9

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

49%73.5

FUNDAMENTALS

Market Cap

$9.3B

P/E (Forward)

—

Gross Margin

59.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KRK.WA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
KRK.WA	Krka, d. d.(you)	$9.3B	98	Strong Buy

Krka, d. d. (KRK.WA): Stock Score Summary

Krka, d. d. (KRK.WA) has a MoatMap StockRank of 98/100 based on Quality (85/100), Value (58/100), and Momentum (71/100) factor scores. The current signal is STRONG BUY. Krka is a quintessential high-ROIC quality compounder with deep operational moats in generic pharmaceuticals. Its ability to maintain pricing power while delivering consistent dividends makes it a defensive anchor during geopolitical instability. The company is well-positioned to benefit from the 'Quality Compounder' macro theme as investors rotate away from cyclical volatility toward reliable earnings.

Key Financial Metrics

Price	$300.99
Market Cap	$9.3B
P/E (TTM)	19.11
Price/Book	3.06
Return on Equity	16.2%
Return on Invested Capital	20.6%
Debt/Equity	0.01x
Gross Margin	59.6%
Operating Margin	28.5%
Revenue Growth	5.2%
Dividend Yield	3.4%
Free Cash Flow	$457M

Krka, d. d. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Slovenia).

Frequently Asked Questions

What is Krka, d. d.’s (KRK.WA) StockRank?: MoatMap’s StockRank for Krka, d. d. (KRK.WA) is 98/100, with a Strong Buy signal. It is a composite of Quality (85), Value (58), and Momentum (71) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Krka, d. d. have an economic moat?: Krka, d. d. (KRK.WA) has a Quality factor score of 85/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Krka, d. d. a buy, hold, or sell?: MoatMap’s current signal for Krka, d. d. (KRK.WA) is Strong Buy, based on a StockRank of 98/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Krka, d. d. in?: Krka, d. d. (KRK.WA) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Slovenia).